Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
JNJ-DGAT2-A
Cat. No.:
0225LY-0724
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
JNJ-DGAT2-A serves as a specific inhibitor of DGAT2 (IC50 = 0.14 micromolar) and is primarily utilized in research concerning triglyceride synthesis.
Synonym:
1962931-71-0; 3-Bromo-4-[2-fluoro-4-[[4-oxo-2-[[2-(pyridin-2-yl)ethyl]amino]-1,3-thiazol-5-(4H)ylidene]methyl]phenoxy]benzonitrile; 3-Bromo-4-(2-fluoro-4-((4-oxo-2-((2-(pyridin-2-yl)ethyl)amino)thiazol-5(4H)-ylidene)methyl)phenoxy)benzonitrile
CAS No.:
1962931-71-0
Compound CID:
137025390
Formula:
C24H16BrFN4O2S
Formula Weight:
523.38
Specification
Targets&IC50:
DGAT-2 (Sf9 insect cell membranes ): 0.14 μM
Relative Density:
1.49 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
JNJ-DGAT2-A can be used in hepatology research to study the reduction of liver triglycerides through the selective inhibition of DGAT2.
Library Information
Target:
DGAT2
Receptor:
DGAT2
Pathways:
Metabolism
Plate Number:
AOCL-10
Plate Location:
c11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
2mM DMSO
DMSO Max Solubility:
3 mg/mL; 5.73 mM
